Compare Marvell Technology Inc (MRVL) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Pfizer Inc — how do they compare? Marvell Technology Inc trades at $270.86 (market cap $246.84B), while Pfizer Inc trades at $27.99 (market cap $158.56B). The key difference: Marvell Technology Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and Pfizer Inc for 158 Days on average.
| MRVL | PFE | |
|---|---|---|
Market Cap | $246.84B | $158.56B |
Volume | 29,003,830 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $316.43 | $29.02 |
52-Week Low | $73.73 | $23.67 |
Typical Hold Time | 42 Days | 158 Days |
Enterprise Value | $248.19B | $210.06B |
Dividend Yield | 0.09% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $284.68, down 0.81% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 expected at $1.1. Revenue growth is accelerating, driven by data center and custom AI chip demand, though current valuations are elevated with a P/E of 90.95. Recent news highlights a major Google deal and raised fiscal 2028 revenue guidance to $18 billion.
The outlook remains positive given robust AI infrastructure spending and management's optimistic forecasts. Key risks include high valuation multiples, competitive pressures, and execution challenges in scaling custom chip production. Analyst consensus is strongly bullish with a $327.86 price target, suggesting significant upside potential if growth targets are met.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
